An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|133|1|29-30

ISSN： 0001-5792

Source： Acta Haematologica, Vol.133, Iss.1, 2014-07, pp. : 29-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 10-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effects of bortezomib on bone disease in patients with multiple myeloma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 618-623

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 114, Iss. 3, 2005-10 ,pp. : 170-173

Karger

Access to resources Recommend Favorite

Severe Epidermal Necrolysis after Bortezomib Treatment for Multiple Myeloma

By  

Acta Haematologica, Vol. 118, Iss. 2, 2007-05 ,pp. : 65-67

Karger

Access to resources Recommend Favorite

Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 184-188

Karger

Access to resources Recommend Favorite